

Bracco Injengineering S.A.
Avenue de Sévelin 46
CH-1004 Lausanne
Switzerland

2nd February 2024

Notified Body Confirmation Letter
Reference: EU2023-607/ 778204

To whom it may concern,

Confirmation of the status of a formal application, written agreement, and appropriate surveillance in the framework of Regulation (EU) 2023/607 amending Regulations (EU) 2017/745 and (EU) 2017/746 as regards the transitional provisions for certain medical devices and in vitro diagnostic medical devices

This letter confirms that, **BSI Group The Netherlands B.V.**, a Notified Body (NB) designated against Regulation (EU) 2017/745 (MDR) and identified by the number **2797** on NANDO, has received a formal application in accordance with Section 4.3, first subparagraph of Annex VII of MDR and has signed a written agreement in accordance with Section 4.3, second subparagraph of Annex VII of MDR with the following manufacturer:

Bracco Injengineering S.A.
Avenue de Sévelin 46
1004 Lausanne
Switzerland

SRN: CH-MF-000019387

The devices covered by the formal application and the written agreement mentioned above are identified in the Tables below. Table 1 identifies the devices for which an MDR application has been received, written agreement concluded and for which the NB is also responsible for appropriate surveillance of the corresponding devices under the applicable Directive. Table 2 identifies the devices for which an MDR application has been received and a written agreement concluded, but the NB has not yet taken the responsibility for appropriate surveillance of the corresponding devices under the applicable Directive.

In the case of devices covered by certificates issued under Directive 90/385/EEC (AIMDD) or Directive 93/42/EEC (MDD) that expired after 26 May 2021 and before 20 March 2023, without having been withdrawn, this letter also confirms that the manufacturer signed the written agreement under MDR by the date of MDD/AIMDD certificate expiry; or provided evidence that a competent authority of a Member State had granted a derogation or exemption from the applicable conformity assessment procedure in accordance with Article 59(1) of MDR or Article 97(1) of the MDR respectively, by the 20 Mar 2023 for the relevant devices.

The transition timelines that apply to the devices covered by this letter, subject to the manufacturer's continued compliance to the other conditions specified in Article 120.3c of MDR (as amended by (EU) 2023/607), are shown below:

- 26 May 2026 for Class III custom-made implantable devices
- 31 December 2027 for Class III devices and Class IIb implantable devices excluding Well-established technologies (WET - sutures, staples, dental fillings, dental braces, tooth crowns, screws, wedges, plates, wires, pins, clips and connectors)
- 31 December 2028 for other Class IIb devices, Class IIa, Class I devices placed on the market in sterile condition or have a measuring function
- 31 December 2028 for devices not requiring the involvement of a notified body under MDD but requiring it under MDR (e.g., class I devices that qualify as re-usable surgical instruments)

On behalf of BSI Group The Netherlands B.V.,

BSI Scheme Manager

Table 1: Devices covered by this letter and for which the NB is also responsible for appropriate surveillance of the corresponding devices under the applicable Directive:

Device name or Basic UDI-DI (under MDR application)	MDR Device classification (as proposed by the manufacturer and verified at the pre-application stage)	If the MDR device is a substitute device, identification of the corresponding MDD/AIMDD device	MDD/AIMDD Certificate Reference(s) of the devices under MDR application, and the NB Identification
CT Exprès 3D/4D, CT Exprès EVO	Class IIb - Non Implantable	Not Applicable	CE 598543, Expires 26 May 2024, NB# 2797
Empower CTA+	Class IIb - Non Implantable	Not Applicable	CE 598543, Expires 26 May 2024, NB# 2797
Empower MR	Class IIb - Non Implantable	Not Applicable	CE 598543, Expires 26 May 2024, NB# 2797
CT Exprès Day Set III HP	Class IIa	Not Applicable	CE 598543, Expires 26 May 2024, NB# 2797
CT Exprès Patient Set & Patient Set EVO	Class IIa	Not Applicable	CE 598543, Expires 26 May 2024, NB# 2797
CT Exprès Bottle Spike	Class IIa	Not Applicable	CE 598543, Expires 26 May 2024, NB# 2797
CT Exprès Multi-Patient Set	Class IIa	Not Applicable	CE 598543, Expires 26 May 2024, NB# 2797
CT Exprès Patient Line	Class IIa	Not Applicable	CE 598543, Expires 26 May 2024, NB# 2797
FastLoad /CT and DCV CTA	Class IIa	Not Applicable	CE 598543, Expires 26 May 2024, NB# 2797
FastLoad /DCV MR	Class IIa	Not Applicable	CE 598543, Expires 26 May 2024, NB# 2797

Confirmation Letter Revision History

BSI Group The Netherlands B.V.
Say Building
John M. Keynesplein 9, 1066 EP
Amsterdam, The Netherlands

bsigroup.com
bsigroup.nl
T: +31 20 346 0780

Page 3 of 4

Validity of this letter may be verified by writing to Certificate.Verification@bsigroup.com



Date	Action
2024/02/02	Initial issue

MB2791